For the 20 years Blonski took Depo-Provera, she thought it was safe. Her lawsuit claims that had she known of the dangers ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted ...

Analysts say TrumpRx, the Trump administration's consumer drug-pricing site, might not deliver lower drug prices for most ...

Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.

Studies show that women who use a contraceptive injection known as Depo-Provera could increase their risk of benign brain ...

Federal prescription drug platform TrumpRx aims to provide most-favored-nation pricing. Physicians discuss potential impact ...

Experts say ‘they’re just coming up with reasons’ as agency says application lacked ‘adequate and well controlled’ trial ...

US trade deal lifts FDI, government leads growth push post-Budget, urban consumers cautious but relief expected soon, underdog Indian founders outperform elite returnees, and more ...

Tammy Croston, from Cupar in Fife, developed four brain tumours after using the contraceptive Depo-Provera for nearly 30 ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu ...

Alnylam has sold off on worries about the short-term health of the TTR market and the company's more aggressive long-term spending plans. Read why ALNY is a Buy.